Lv3
398 积分 2021-08-11 加入
Rethinking ovarian cancer III: the past decade and future directions
1天前
已完结
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy
1天前
已完结
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial
1天前
已完结
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer
1天前
已完结
Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial
1天前
已完结
HR阳性HER2阴性晚期乳腺癌内脏转移及内脏危象诊治专家共识（2025版）
3个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
4个月前
已完结
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363
4个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
5个月前
已完结
皖公网安备34019202002308
